"Best Practices" for FDA Advisory Committees
This article was originally published in RPM Report
Executive Summary
The Food & Drug Administration has wrapped up an extensive review of the advisory committee process with a plan to implement "best practices" across its system of outside expert panels. The changes, which were announced as part of FDA's response to the Institute of Medicine report on drug safety, include three guidances slated for release in 2007.
You may also be interested in...
Reconstructing Advisory Committees: FDA Conflict of Interest Policy Will Pose Challenges for Drug Sponsors
Drug sponsors soon will have another hurdle to overcome at advisory committee meetings: significant turnover in the experts asked to consider the approvability of their products. The new policy will help FDA quiet critics of the agency's advisory committee system, but it will also create more noise around the drug approval process.
FDA's Selective Response to the IoM Drug Safety Report
FDA says its plan to improve the post-marketing drug safety system embraces most of the recommendations made by the Institute of Medicine in a 2006 report. But in several respects, the agency's response isn't exactly what IoM had in mind.
FDA's Selective Response to the IoM Drug Safety Report
FDA says its plan to improve the post-marketing drug safety system embraces most of the recommendations made by the Institute of Medicine in a 2006 report. But in several respects, the agency's response isn't exactly what IoM had in mind.